179 related articles for article (PubMed ID: 27843694)
1. Grey matter abnormalities in methcathinone abusers with a Parkinsonian syndrome.
Juurmaa J; Menke RA; Vila P; Müürsepp A; Tomberg T; Ilves P; Nigul M; Johansen-Berg H; Donaghy M; Stagg CJ; Stepens A; Taba P
Brain Behav; 2016 Nov; 6(11):e00539. PubMed ID: 27843694
[TBL] [Abstract][Full Text] [Related]
2. The outcome of the movement disorder in methcathinone abusers: clinical, MRI and manganesemia changes, and neuropathology.
Stepens A; Groma V; Skuja S; Platkājis A; Aldiņš P; Ekšteina I; Mārtiņsone I; Bricis R; Donaghy M
Eur J Neurol; 2014 Feb; 21(2):199-205. PubMed ID: 23678867
[TBL] [Abstract][Full Text] [Related]
3. White matter abnormalities in methcathinone abusers with an extrapyramidal syndrome.
Stepens A; Stagg CJ; Platkajis A; Boudrias MH; Johansen-Berg H; Donaghy M
Brain; 2010 Dec; 133(Pt 12):3676-84. PubMed ID: 21036949
[TBL] [Abstract][Full Text] [Related]
4. Manganese-induced Parkinsonism associated with methcathinone (Ephedrone) abuse.
de Bie RM; Gladstone RM; Strafella AP; Ko JH; Lang AE
Arch Neurol; 2007 Jun; 64(6):886-9. PubMed ID: 17562938
[TBL] [Abstract][Full Text] [Related]
5. A Parkinsonian syndrome in methcathinone users and the role of manganese.
Stepens A; Logina I; Liguts V; Aldins P; Eksteina I; Platkājis A; Mārtinsone I; Tērauds E; Rozentāle B; Donaghy M
N Engl J Med; 2008 Mar; 358(10):1009-17. PubMed ID: 18322282
[TBL] [Abstract][Full Text] [Related]
6. Manganese-induced parkinsonism in methcathinone abusers: bio-markers of exposure and follow-up.
Sikk K; Haldre S; Aquilonius SM; Asser A; Paris M; Roose Ä; Petterson J; Eriksson SL; Bergquist J; Taba P
Eur J Neurol; 2013 Jun; 20(6):915-20. PubMed ID: 23347399
[TBL] [Abstract][Full Text] [Related]
7. Manganese Encephalopathy among Ephedron Abusers.
Janocha-Litwin J; Marianska K; Serafinska S; Simon K
J Neuroimaging; 2015; 25(5):832-5. PubMed ID: 25255816
[TBL] [Abstract][Full Text] [Related]
8. Acute hyperkinetic syndrome due to ephedrone abuse.
Dolgan A; Budrewicz S; Koszewicz M; Bladowska J; Slotwinski K; Zagrajek M; Koziorowska-Gawron E; Podemski R
J Addict Med; 2015; 9(3):244-5. PubMed ID: 25835774
[TBL] [Abstract][Full Text] [Related]
9. Parkinsonism caused by chronic usage of intravenous potassium permanganate.
Meral H; Kutukcu Y; Atmaca B; Ozer F; Hamamcioglu K
Neurologist; 2007 Mar; 13(2):92-4. PubMed ID: 17351530
[TBL] [Abstract][Full Text] [Related]
10. Unusual magnetic resonance imaging of the head in manganese and ephedrone intoxication - a case report.
Jastrzębski K; Gałecki P; Sanchez SI
Pol Merkur Lekarski; 2021 Dec; 49(294):434-436. PubMed ID: 34919088
[TBL] [Abstract][Full Text] [Related]
11. Cognitive impairment and structural brain damage in multiple system atrophy-parkinsonian variant.
Caso F; Canu E; Lukic MJ; Petrovic IN; Fontana A; Nikolic I; Kostic VS; Filippi M; Agosta F
J Neurol; 2020 Jan; 267(1):87-94. PubMed ID: 31559533
[TBL] [Abstract][Full Text] [Related]
12. Grey matter volume loss is associated with specific clinical motor signs in Huntington's disease.
Coppen EM; Jacobs M; van den Berg-Huysmans AA; van der Grond J; Roos RAC
Parkinsonism Relat Disord; 2018 Jan; 46():56-61. PubMed ID: 29128164
[TBL] [Abstract][Full Text] [Related]
13. Manganic encephalopathy due to "ephedrone" abuse.
Sanotsky Y; Lesyk R; Fedoryshyn L; Komnatska I; Matviyenko Y; Fahn S
Mov Disord; 2007 Jul; 22(9):1337-43. PubMed ID: 17566121
[TBL] [Abstract][Full Text] [Related]
14. Clinical, neuroimaging and neurophysiological features in addicts with manganese-ephedrone exposure.
Sikk K; Taba P; Haldre S; Bergquist J; Nyholm D; Askmark H; Danfors T; Sörensen J; Thurfjell L; Raininko R; Eriksson R; Flink R; Färnstrand C; Aquilonius SM
Acta Neurol Scand; 2010 Apr; 121(4):237-43. PubMed ID: 20028341
[TBL] [Abstract][Full Text] [Related]
15. Methcathinone "Kitchen Chemistry" and Permanent Neurological Damage.
Sikk K; Taba P
Int Rev Neurobiol; 2015; 120():257-71. PubMed ID: 26070761
[TBL] [Abstract][Full Text] [Related]
16. Increased reflection impulsivity in patients with ephedrone-induced Parkinsonism.
Djamshidian A; Sanotsky Y; Matviyenko Y; O'Sullivan SS; Sharman S; Selikhova M; Fedoryshyn L; Filts Y; Bearn J; Lees AJ; Averbeck BB
Addiction; 2013 Apr; 108(4):771-9. PubMed ID: 23228208
[TBL] [Abstract][Full Text] [Related]
17. Parkinsonism and dystonia caused by the illicit use of ephedrone--a longitudinal study.
Selikhova M; Fedoryshyn L; Matviyenko Y; Komnatska I; Kyrylchuk M; Krolicki L; Friedman A; Taylor A; Jäger HR; Lees A; Sanotsky Y
Mov Disord; 2008 Nov; 23(15):2224-31. PubMed ID: 18785245
[TBL] [Abstract][Full Text] [Related]
18. Developmentally stable whole-brain volume reductions and developmentally sensitive caudate and putamen volume alterations in those with attention-deficit/hyperactivity disorder and their unaffected siblings.
Greven CU; Bralten J; Mennes M; O'Dwyer L; van Hulzen KJ; Rommelse N; Schweren LJ; Hoekstra PJ; Hartman CA; Heslenfeld D; Oosterlaan J; Faraone SV; Franke B; Zwiers MP; Arias-Vasquez A; Buitelaar JK
JAMA Psychiatry; 2015 May; 72(5):490-9. PubMed ID: 25785435
[TBL] [Abstract][Full Text] [Related]
19. Automated segmentation of cerebral deep gray matter from MRI scans: effect of field strength on sensitivity and reliability.
Chu R; Hurwitz S; Tauhid S; Bakshi R
BMC Neurol; 2017 Sep; 17(1):172. PubMed ID: 28874119
[TBL] [Abstract][Full Text] [Related]
20. Neurotoxicity following chronic intravenous use of "Russian cocktail".
Varlibas F; Delipoyraz I; Yuksel G; Filiz G; Tireli H; Gecim NO
Clin Toxicol (Phila); 2009 Feb; 47(2):157-60. PubMed ID: 18608260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
